See all treatments in the PatientsLikeMe system shared by patients just like you.
Brand Names:
Copaxone
What is Glatiramer acetate? Glatiramer acetate combines four amino acids including L-alanine, L-glutamic acid, L-lysine and L-tyrosine. It is used for Relapsing-Remitting Multiple Sclerosis (RRMS) to reduce the frequency and severity of relapses. It is administered as a subcutaneous injection.
See more information, including instructions, precautions, side effects, and interactions.
2657 patients in the community are taking or have taken Glatiramer acetate.
Top 10 (Show all)
| Reason | # Patients | Percentage of patients |
|---|---|---|
| Slow my MS progress | 2001 | 75% |
| Other | 105 | 3% |
| General health | 35 | 1% |
| Stiffness/Spasticity | 27 | 1% |
| Don't know | 17 | <1% |
| Fatigue | 12 | <1% |
| Multiple Sclerosis (MS) | 12 | <1% |
| Pain | 8 | <1% |
| disease-related symptoms | 8 | <1% |
| Bladder problems | 7 | <1% |
Other treatments patients are taking for Slow my MS progress include Interferon beta-1a IM Injection, Interferon beta-1a SubQ injection, and Interferon beta-1b SubQ Injection.
Based on the patients currently taking Glatiramer acetate.
Top 10 (Show all)
All (Show top 10)
| 20mg as needed | 20mg/mL as needed | 20mg weekly | daily | 1 mL weekly | 0.2 mg daily | 1 daily | 1 g daily | 1 mg daily | 1 mL daily | 2 mg daily | 20 mg weekly | 5 mg daily | 40 mg weekly | 10 mg daily | 20 mg | 20 mg every other day | 13 mg daily | 15 mg daily | 20 daily | 20 mcg daily | 20 mg daily | 20 mg one time | 22 mg daily | 25 mg daily | 30 mg daily | 40 mg daily | 44 mg daily | 50 mg daily | 60 mg daily | 80 mg daily | 81 mg daily | 100 mg daily | 120 mg daily | 200 mg daily | 250 mg daily | 300 mg daily | 1200 mg daily | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
2
|
1
|
1
|
240
|
1
|
1
|
6
|
1
|
42
|
3
|
2
|
3
|
2
|
1
|
12
|
1
|
23
|
1
|
1
|
1
|
1
|
1545
|
1
|
1
|
5
|
7
|
6
|
3
|
3
|
6
|
1
|
1
|
3
|
1
|
9
|
1
|
1
|
1
|
||
How long current patients have been taking Glatiramer acetate or how long patients were taking Glatiramer acetate before stopping.
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Did not seem to work | 287 | 40% | |
| Side effects too severe | 248 | 35% | |
| Doctor's advice | 190 | 26% | |
| Other | 145 | 20% | |
| Expense | 53 | 7% | |
| Personal research | 32 | 4% | |
| Not indicated | 12 | 2% | |
| Course of treatment ended | 7 | 1% |
Results from 487 patient evaluations. See the overall results and all individual evaluations.
| Major | 16% | 69 |
|---|---|---|
| Moderate | 15% | 68 |
| Slight | 9% | 39 |
| None | 7% | 29 |
| Can't tell | 54% | 238 |
Slow my MS progress
| Severe | 9% | 43 |
|---|---|---|
| Moderate | 15% | 73 |
| Mild | 50% | 245 |
| None | 26% | 126 |
Top reported side-effects include: lumps, Injection site reaction, redness
Summary results are based on 487 individual responses. For more information, see overall results for Adherence, Burden and Cost.
Report created on November 07, 2009.